The CDCM bridges the divide between laboratory discovery and translation to patients in clinical trials
What is CDCM?
The Center for Definite and Curative Medicine (CDCM) is a joint initiative of the Stanford University School of Medicine, Stanford Health Care and Stanford Children’s Health. It is co-directed by Drs. Maria Grazia Roncarolo, Anthony Oro, and Matthew Porteus.
The CDCM provides the know-how, organizational and physical infrastructure to support investigator-initiated clinical translational studies on cell and gene therapy (CGT) from initial discovery through completion of clinical proof-of-concept trials. Stanford Medicine’s clinical enterprise provides an exemplary clinical environment in which to deploy cures. The CDCM will support the development of life-changing and curative treatments for patients who come to Stanford to receive the highest level of care.
Why CDCM?
A number of distinguishing features make Stanford particularly well-positioned to succeed
Pre-eminent, highly-funded cell and gene therapy program
Significant investment in translational infrastructure on campus
Newly built state-of-the-art GMP facility
Excellence in clinical care and access to patient populations
News
Rocket Pharmaceuticals Announces FDA Clearance of IND Application for RP-L102 Gene Therapy for Fanconi Anemia
NEW YORK – November 7, 2018 - Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT) (“Rocket”)
California Institute for Regenerative Medicine (CIRM) Funding Announcement
Congratulations to Vittorio Sebastiano and Katja Weinacht for being awarded a CIRM grant to develop a therapeutic product for children with 22q11 Deletion Syndrome!
Maria Grazia-Roncarolo, MD, appointed President of FOCIS
Maria Grazia-Roncarolo, MD appointed President of FOCIS! The Federation of Clinical Immunology Societies (FOCIS) exists to improve human health through immunology by fostering interdisciplinary approaches to both understand and treat immune-based diseases.
Rocket Pharma Collaboration
The Center for Definitive and Curative Medicine (CDCM) at Stanford Medicine has entered into a collaborative research agreement with Rocket Pharmaceuticals, Inc. to further the CDCM’s mission of curing the seemingly incurable.